Please login to the form below

Not currently logged in
Email:
Password:

Takeda enters partnership over Contrave

Takeda and Orexigen have entered into a partnership to commercialise investigational obesity drug Contrave in North America

Takeda Pharmaceuticals and Orexigen Therapeutics have entered into a partnership to commercialise investigational obesity drug Contrave (naltrexone SR/bupropion SR) in North America.

Under the agreement, Japan-based Takeda will pay Orexigen an upfront cash payment of $50m with Takeda obtaining exclusive marketing rights for the drug in the US, Mexico and Canada. Orexigen, a biopharmaceutical company focused on the treatment of obesity, will retain co-promotion rights with Takeda in the US.

Further regulatory and sales-based milestones of over $1bn are also available to Orexigen if achieved. Takeda will pay tiered double-digit royalty payments on net sales if Contrave is commercialised in North America.

Both companies will work together on ongoing development of the product, with future development costs to be shared.

"We believe this is a great strategic partnership to enable our goal of a strong market entry for Contrave, if approved," said Michael Narachi, president and CEO of Orexigen.

"It has been our belief that getting a partner involved early would be critical to a high-quality launch of Contrave, and with this partnership now in place, we are tightly focused on the regulatory review process and securing approval for Contrave," Narachi said.

Contrave is developed as a combination therapy to treat both biological and behavioural issues with obesity.

A New Drug Application (NDA) was submitted by Orexigen to the US Food and Drug Administration (FDA) in March 2010.

2nd September 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Healthcare Media Europe – HME Ltd

HME are an innovative and technology enabled agency offering our clients over 35+ years of knowledge and expertise in delivering...

Latest intelligence

Theresa Heggie
Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe
Theresa Heggie talks about the biotech’s 16-year path to market, and the promise of its ‘gene silencing’ medicines...
patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...

Infographics